LILRB4 deficiency aggravates the development of atherosclerosis and plaque instability by increasing the macrophage inflammatory response via NF-{kappa}B signaling

In conclusion, the present study indicates that LILRB4 deficiency promotes atherogenesis, at least partly, through reduced Shp1 phosphorylation, which subsequently enhances the NF-B-mediated inflammatory response. Thus, targeting the "LILRB4-Shp1" axis may be a novel therapeutic approach for atherosclerosis.

Source: Clinical Science - July 25, 2017 Category: Biomedical Science Authors: Jiang, Z., Qin, J.-J., Zhang, Y., Cheng, W.-L., Ji, Y.-X., Gong, F.-H., Zhu, X.-Y., Zhang, Y., She, Z.-G., Huang, Z., Li, H. Tags: PublishAheadOfPrint Source Type: research